Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation.
OBJECTIVE
We investigated the effects of treatment with the angiotensin II type 1 receptor antagonist, telmisartan, on abdominal aortic aneurysm formation in normotensive rats.


METHODS
Abdominal aortic aneurysm was induced by perfusion of an isolated aortic segment with elastase. Treatment with telmisattan (0.5 mg/kg per day) or hydralazine (15 mg/kg per day) was started after surgery and continued for 14 days. Sham-operated animals and vehicle-treated animals after aneurysm induction served as controls. Aortic diameter was measured using ultrasound before aneurysm induction and on days 7 and 14 after aneurysm induction.


RESULTS
On day 14, aortic diameter was increased two-fold in the vehicle-treated group compared to sham-operated animals (2.02 +/- 0.12 vs. 0.87 +/- 0.02 mm, P < 0.005, n = 8). Telmisartan treatment significantly reduced aneurysmal size (1.65 +/- 0.06 vs. 2.02 +/- 0.12 mm in vehicle, P < 0.05, n = 8), whereas treatment with hydralazine had no effect. Matrix metallopeptidase 3, cathepsin D, nuclear factor kappa B, tumour necrosis factor alpha, transforming growth factor-1 beta, as well as caspase 3, p53 and Fas ligand proteins, were significantly downregulated in aortic tissue under telmisartan compared to vehicle treatment. Serum monocyte chemoattractant protein 1 levels were also significantly decreased. Telmisartan and hydralazine reduced blood pressure to a similar extent within the observation period.


CONCLUSIONS
The angiotensin II type 1 receptor antagonist, telmisartan, prevents abdominal aortic aneurysm progression independently of blood pressure reduction by inhibiting proteolysis, apoptosis and inflammation in aortic tissue.
Kaschina
Elena
E
Center for Cardiovascular Research (CCR)/Institute of Pharmacology, Charité Universitätsmedizin Berlin, Berlin, Germany. elena.kaschina@charite.de
Schrader
Felix
F
Sommerfeld
Manuela
M
Kemnitz
Ulrich Rudolf
UR
Grzesiak
Aleksandra
A
Krikov
Maxim
M
Unger
Thomas
T
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001012:Aorta, Abdominal / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D017544:Aortic Aneurysm, Abdominal / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D017209:Apoptosis / Q000187:drug effects*; D001562:Benzimidazoles / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002402:Cathepsin D / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006830:Hydralazine / Q000494:pharmacology; D007249:Inflammation / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D011489:Protein Denaturation / Q000187:drug effects*; D051381:Rats; D011914:Rats, Inbred BN; D000077333:Telmisartan; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D006830:Hydralazine; D002402:Cathepsin D; D019278:Matrix Metalloproteinase 3; D000077333:Telmisartan